-
Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions.
J Infect Dis. 2003 Nov 15;188(10):1433-43
PMID: 14624368
-
Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples.
AIDS Res Hum Retroviruses. 1998 Jul 1;14(10):869-76
PMID: 9671215
-
Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors.
J Virol. 2004 Apr;78(8):4234-47
PMID: 15047838
-
Fidelity of HIV-1 reverse transcriptase.
Science. 1988 Nov 25;242(4882):1168-71
PMID: 2460924
-
Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. ACTG Sequencing Working Group. AIDS Clinical Trials Group.
J Virol Methods. 1998 Nov;75(1):93-104
PMID: 9820578
-
Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.
Lancet. 1999 Jun 26;353(9171):2195-9
PMID: 10392984
-
Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.
J Infect Dis. 2010 Mar;201(5):672-80
PMID: 20102272
-
Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection.
J Virol. 1999 Dec;73(12):10489-502
PMID: 10559367
-
A strategy for cloning infectious molecular clones of retroviruses from serum or plasma.
J Virol Methods. 2000 Jan;84(1):37-48
PMID: 10644085
-
The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan.
Antivir Ther. 2000 Mar;5(1):41-8
PMID: 10846592
-
A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.
AIDS. 2000 Jun 16;14(9):F83-93
PMID: 10894268
-
Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy.
Antimicrob Agents Chemother. 2000 Sep;44(9):2475-84
PMID: 10952598
-
Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.
N Engl J Med. 2001 Feb 15;344(7):472-80
PMID: 11172188
-
Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance.
AIDS. 2001 Feb 16;15(3):309-20
PMID: 11273210
-
Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy.
J Virol. 2001 Jul;75(14):6410-7
PMID: 11413308
-
Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure.
AIDS. 2001 Nov 9;15(16):2189-91
PMID: 11684940
-
Reappearance of HIV multidrug-resistance in plasma and circulating lymphocytes after reintroduction of antiretroviral therapy.
J Clin Virol. 2002 Feb;24(1-2):93-8
PMID: 11744433
-
Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program.
AIDS Res Hum Retroviruses. 2002 Mar 1;18(4):243-8
PMID: 11860670
-
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
JAMA. 2002 Jul 10;288(2):169-80
PMID: 12095381
-
Molecular basis of fidelity of DNA synthesis and nucleotide specificity of retroviral reverse transcriptases.
Prog Nucleic Acid Res Mol Biol. 2002;71:91-147
PMID: 12102562
-
Virus population homogenization following acute human immunodeficiency virus type 1 infection.
J Virol. 2002 Dec;76(23):11953-9
PMID: 12414937
-
Retroviral mutation rates and reverse transcriptase fidelity.
Front Biosci. 2003 Jan 1;8:d117-34
PMID: 12456349
-
From RNA to quasispecies: a DNA polymerase with proofreading activity is highly recommended for accurate assessment of viral diversity.
J Virol Methods. 2003 May;109(2):161-70
PMID: 12711059
-
Multiple sequence alignment with the Clustal series of programs.
Nucleic Acids Res. 2003 Jul 1;31(13):3497-500
PMID: 12824352
-
HIV sequence databases.
AIDS Rev. 2003 Jan-Mar;5(1):52-61
PMID: 12875108
-
Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus.
N Engl J Med. 2003 Aug 28;349(9):837-46
PMID: 12944569
-
HIV resistance testing. A clinical tool.
N J Med. 2003 Sep;100(9 Suppl):44-9; quiz 75-6
PMID: 14556603
-
The accuracy of reverse transcriptase from HIV-1.
Science. 1988 Nov 25;242(4882):1171-3
PMID: 2460925
-
Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1.
J Virol. 1990 Dec;64(12):5840-50
PMID: 2243378
-
Detection, quantification and sequencing of HIV-1 from the plasma of seropositive individuals and from factor VIII concentrates.
AIDS. 1991 Jun;5(6):675-81
PMID: 1715717
-
Convergent and divergent sequence evolution in the surface envelope glycoprotein of human immunodeficiency virus type 1 within a single infected patient.
Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):4835-9
PMID: 1594583
-
Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy.
J Virol. 1994 Mar;68(3):1660-6
PMID: 7509000
-
Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy.
J Virol. 1995 Jan;69(1):23-31
PMID: 7983713
-
CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.
Nucleic Acids Res. 1994 Nov 11;22(22):4673-80
PMID: 7984417
-
HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy.
Science. 1995 Jan 27;267(5197):483-9
PMID: 7824947
-
In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.
Nature. 1995 Apr 6;374(6522):569-71
PMID: 7700387
-
Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.
J Virol. 1995 Aug;69(8):5087-94
PMID: 7541846
-
Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization.
PCR Methods Appl. 1995 Jun;4(6):357-62
PMID: 7580930
-
HIV quasispecies and resampling.
Science. 1996 Jul 26;273(5274):415-6
PMID: 8677432
-
Independent evolution of the env and pol genes of HIV-1 during zidovudine therapy.
AIDS. 1996 Sep;10(10):1067-73
PMID: 8874622
-
Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients.
J Virol. 1996 Nov;70(11):7894-9
PMID: 8892912
-
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor.
J Virol. 1996 Dec;70(12):8270-6
PMID: 8970946
-
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel.
JAMA. 1997 Jun 25;277(24):1962-9
PMID: 9200638
-
Evolution of human immunodeficiency virus type 1 envelope sequences in infected individuals with differing disease progression profiles.
Virology. 1998 Feb 15;241(2):251-9
PMID: 9499799
-
Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment.
J Virol. 1998 Jun;72(6):5303-6
PMID: 9573309
-
Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients.
Ann Intern Med. 1998 Jun 1;128(11):906-11
PMID: 9634429
-
Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine.
J Infect Dis. 2004 Mar 15;189(6):1091-6
PMID: 14999613